

Kluwer Patent Blog

Patent case: Actavis Group PTC EHF v ICOS Corporation, United Kingdom

Sara Moran · Saturday, December 15th, 2018

The Court of Appeal overturned the Patent Court's first instance decision concerning the validity of one of ICOS's patents (licensed to Eli Lilly) covering a 1 to 5mg dosage form of tadalafil (Cialis®) for oral administration up to a maximum of 5mg per day for the treatment of sexual dysfunction. The Court held that the Judge had erred in concluding that the patent was not obvious, and made interesting comments on the requirement that the person skilled in the art would have a reasonable expectation of success in trying the invention.

Case date: 01 November 2017

Case number: [2017] EWCA Civ 1671

Court: Court of Appeal of England and Wales, Civil Division

A full summary of this case has been published on [Kluwer IP Law](#).

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe [here](#).



Want to improve your IP strategy?

- Manual of Industrial Property
- IP Analytics
- Visser – Annotated European Patent Convention

230+ jurisdictions
36,000+ cases
100+ books
600+ IP law professionals as authors

Request a free demo now
KluwerIPLaw.com

Wolters Kluwer

This entry was posted on Saturday, December 15th, 2018 at 4:55 am and is filed under [Case Law](#), [Pharmaceutical patent](#), [United Kingdom](#)

You can follow any responses to this entry through the [Comments \(RSS\)](#) feed. Both comments and pings are currently closed.